



Issued – Tuesday 8 May 2007, London, UK, Philadelphia, PA & Houston, TX

FABRE-KRAMER REFILES *GEPİRONE ER* WITH THE FDA FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

Fabre-Kramer Pharmaceuticals Inc. and GlaxoSmithKline announced today the submission by Fabre-Kramer to the Food and Drug Administration of an amendment to the New Drug Application for gepirone extended release (ER). The amendment responds to the FDA's June 2004 request for an additional positive short term efficacy trial for gepirone ER.

Fabre-Kramer is seeking marketing approval of *gepirone ER* for the treatment of major depressive disorder. Fabre-Kramer and GlaxoSmithKline entered an agreement in February of this year for collaboration on the worldwide development and commercialization of *gepirone ER*.

About Fabre-Kramer Pharmaceuticals

Fabre-Kramer Pharmaceuticals, headquartered in Houston, Texas is engaged in acquiring, developing and commercializing psychotropic drugs that have significant market potential. In addition to gepirone ER, Fabre-Kramer has 10 other compounds in various stages of development for indications including depression, anxiety, schizophrenia, Parkinson's disease and insomnia. For more information, visit FKP's website at www.fabrekramer.com

About GlaxoSmithKline

GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit GlaxoSmithKline on the World Wide Web at www.gsk.com.

GlaxoSmithKline enquiries:

US Product Communications	Marc Meachem	(919) 483-2839
UK Media enquiries:	Philip Thomson	(020) 8047 5502
	Joss Mathieson	(020) 8047 5502
	Gwenan White	(020) 8047 5502
US Media enquiries:	Nancy Pekarek	(215) 751 7709
	Alice Hunt	(215) 751 7709
	Mary Anne Rhyne	(919) 483 2839
European Analyst/Investor enquiries:	Anita Kidgell	(020) 8047 5542
	David Mawdsley	(020) 8047 5564
	Sally Ferguson	(020) 8047 5543
US Analyst/ Investor enquiries:	Frank Murdolo	(215) 751 7002
	Tom Curry	(215) 751 5419

Fabre Kramer enquiries:

Edward H Koehler, Jr. Executive Vice President	(713) 975 6900
---	----------------